Next Article in Journal
Advances in Periodontal Diagnostics: Application of MultiModal Language Models in Visual Interpretation of Panoramic Radiographs
Previous Article in Journal
Precision in Practice: Clinical Indication-Specific DRLs for Head CT for Advanced Personalised Dose Benchmarking
Previous Article in Special Issue
Structural and Hormonal Changes in Reproductive-Age Women Post-COVID-19: A Cross-Sectional Ultrasound and Biochemical Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 15
Issue 15
10.3390/diagnostics15151850
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparing the Diagnostic Efficacy of Different Calcitonin Stimulation Tests for Sporadic Medullary Thyroid Carcinoma: Calcium Gluconate vs. Calcium Chloride

by
Jovan Ilic
1,
Katarina Tausanovic
1,2,
Goran Zoric
1,
Milan Jovanovic
1,2,
Matija Buzejic
1,
Sara Ivanis
1,
Milan Parezanovic
1,
Milan Marinkovic
1,
Nemanja Karamarkovic
2,3,
Ana Petakov
4 and
Vladan Zivaljevic
1,2,*
1
Clinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia
2
School of Medicine, University of Belgrade, 11000 Belgrade, Serbia
3
Clinic for Cardiosurgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia
4
Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, 11000 Belgrade, Serbia
*
Author to whom correspondence should be addressed.
Diagnostics 2025, 15(15), 1850; https://doi.org/10.3390/diagnostics15151850
Submission received: 15 May 2025 / Revised: 17 July 2025 / Accepted: 21 July 2025 / Published: 23 July 2025
(This article belongs to the Special Issue Biochemical Testing Applications in Clinical Diagnosis)
Browse Figures
Versions Notes

Abstract

Background: Medullary thyroid carcinoma (MTC) is a rare malignancy derived from parafollicular C-cells, with calcitonin (Ct) as its key biomarker. While basal Ct (bCt) levels above 100 pg/mL strongly suggest MTC, intermediate elevations (10–100 pg/mL) may reflect C-cell hyperplasia (CCH) or other benign conditions, making diagnostics challenging. Although calcium stimulation testing enhances sensitivity, the optimal cut-off values and comparative efficacy of calcium gluconate (CG) versus calcium chloride (CC) remain insufficiently researched. Methods: Data on 176 patients who underwent total thyroidectomy between 2009 and 2025 were retrospectively analyzed. BCt values ranged from 10 to 100 pg/mL, and stimulated Ct (sCt) values were above 100 pg/mL. CG was used from 2009 to 2019, and CC was used from 2020 to 2025. Definitive pathohistological findings divided patients into those with MTC, CCH, or no C-cell pathology. Receiver operating characteristic (ROC) analysis identified optimal Ct thresholds for predicting MTC for each stimulatory agent. Results: Of the 176 patients, 36 (20.5%) had confirmed MTC. A bCt threshold of 31.1 pg/mL yielded 69.4% sensitivity and 87.1% specificity. For sCt, optimal cut-offs were 810.8 pg/mL for CG and 1076 pg/mL for CC. Lower thresholds (388.4 pg/mL for CG and 431.5 pg/mL for CC) improved sensitivity (≥76.9%) and negative predictive value (>91%). Conclusions: Calcium stimulation testing improves MTC detection in patients with moderate bCt elevation. Although CG showed marginally better diagnostic performance, CC remains a practical and reliable alternative, especially when higher cut-off values are considered. Early surgical intervention should be considered when sensitivity-driven thresholds are met.

1. Introduction

Medullary thyroid carcinoma (MTC) is a neuroendocrine malignant tumor derived from calcitonin (Ct)-producing C-cells of the thyroid gland [1,2,3]. About 20–25% of MTCs are familial, including multiple endocrine neoplasia (MEN) 2 and its subtypes [3]. The 10-year overall survival rate for patients with MTC ranges from 100% to 21% depending on the stage of the disease (I-IV). If the patient becomes biochemically disease-free (with normalized calcitonin levels), which occurs in 43% of operated cases, the survival rate is excellent, amounting to 97.7% at 10 years [2,4]. The most important biomarker for diagnosing MTC is the measurement of Ct. Normal basal Ct (bCt) levels are typically below 10 ng/mL, with physiological values generally higher in males, likely due to the greater C-cell mass in men [5,6]. The Ct value, which confirms the diagnosis of MTC with nearly 100% specificity, is greater than 100 pg/mL [5,7,8,9]. Ct can be slightly elevated in smokers, in patients taking proton pump inhibitors, and in patients with chronic renal failure, autoimmune thyroiditis, and small-cell lung cancer [10,11,12]. However, the most prevalent entity accountable for a moderate elevation of bCt (10–100 pg/mL) is C-cell hyperplasia (CCH), defined as an increase in the number of C-cells [13]. The two subtypes of CCH are reactive (RCCH) and neoplastic (NCCH) [14], which can be histologically distinguished by the presence of spindle-shaped cells and nuclear polymorphisms present in NCCH [15]. RCCH has no malignant potential [14], but it is seldom present in thyroid tissue with follicular cell malignancies [16]. NCCH, on the other hand, is considered a preneoplastic condition associated with familial forms of MTC [14], although cases of NCCH in patients with no mutation in the RET oncogene have been described [17]. This makes it even more challenging to select cases for thyroidectomy, since every CCH would have the potential to be associated with some thyroid malignancy. In these cases, the stimulation test is performed to increase the sensitivity of Ct testing, either by pentagastrin (Pg), an agent that is no longer available in the US, Europe, and South America [18,19], or by application of intravenous calcium, a more available, cheaper, safer, and potentially more potent secretagogue [19,20,21,22]. However, since there are no widely accepted cut-off values for stimulated Ct (sCt), an overlap between CCH and MTC still occurs [23]. Calcium gluconate (CG) is the most commonly referenced calcium agent in the contemporary literature [6,24]. Although calcium chloride (CC) has previously been described as a secretagogue, it has not been commonly used in recent studies [25,26]. Furthermore, since no published studies have directly compared the diagnostic efficacy of stimulation tests using these two calcium agents, the primary aim of the present study was to evaluate and compare the effectiveness of calcium gluconate and calcium chloride in eliciting a diagnostic biochemical response during stimulation testing.

2. Materials and Methods

This retrospective study analyzed clinical data on patients who underwent surgical treatment for elevated calcitonin levels and suspected MTC between January 2009 and January 2025 at the Clinic for Endocrine Surgery, University Clinical Center of Serbia. The data were obtained by reviewing medical histories, including operative and pathohistological (PH) findings using the prospectively maintained electronic database implemented into the institution’s routine clinical practice.
All patients whose bCt was higher than 100 pg/mL underwent surgery. Patients whose bCt levels were between 10 and 100 pg/mL were referred for a calcium stimulation test. In all patients included in the study, other causes of hypercalcitoninemia (use of proton pump inhibitors, renal insufficiency, other neuroendocrine malignancies, pseudohypoparathyroidism, and hypergastrinemia) were excluded. Patients with advanced kidney disease, hypercalcemia, arrhythmogenic cardiac conditions, or a history of myocardial infarction were excluded from undergoing the test due to contraindications. Additionally, patients with a family history of MTC, as well as those with proven MEN 2 syndrome, were excluded from the study.
Patients diagnosed between 2009 and 2019 were tested using CG, while those diagnosed from 2020 to 2025 underwent testing with CC. This series includes data from our previously published study involving 74 patients tested exclusively with CG [27]. Prior to testing, all patients provided informed consent after being informed of the potential side effects. A peripheral venous cannula was placed, and a bCt sample was collected at time 0. The stimulation test was conducted by intravenously administering either 8.5% CG (2.5 mg/kg) or 3% CC (calculated as body mass × 2/8.08) over a 60-second period. Following the injection, blood samples were collected at 1, 3, 5, 8, and 10 min to measure calcitonin levels, with the peak value used for analysis.
According to the definitive PH findings, the operated patients were divided into three groups: those with MTC, CCH, or without any C-cell pathology. Associated thyroid gland pathology was also recorded.

Statistical Analysis

Statistical analyses were performed using IBM SPSS for Windows, version 25.0. Statistical significance is defined as p ≤ 0.05. Numerical results are presented as mean values with standard deviation. An independent samples t-test was used for comparison of numerical values among different groups. Pearson’s correlation coefficient with bootstrapping was performed for correlation testing, and the scatterplot was used for graphical presentation of the data.
Optimal Ct cut-off values that can reliably diagnose MTC preoperatively were determined using receiver operator characteristics (ROC) analysis and calculating the Youden index (= sensitivity + specificity − 1) for three diagnostic groups: (1) bCt, (2) sCt after the application of CG, and (3) sCt after the application of CC. The strength of the statistic test was determined by the area under the curve (AUC). Sensitivity (Sn) and specificity (Sp) were calculated and presented as percentages, with specificity defined as 1—sensitivity. The positive predictive value (PPV) and negative predictive value (NPV) were subsequently determined using the optimal Ct cut-off values based on the following formulas: PPV = true positives/(true positives + false positives); NPV = true negatives/(true negatives + false negatives).

3. Results

Between January 2009 and January 2025, a total of 12,284 patients were operated on in our clinic for various thyroid gland diseases. During this period, MTC was confirmed in 272 patients, making the prevalence of MTC in our series 2.2%.
A total of 176 patients (106 women and 70 men—Table 1), in whom bCt levels were between 10 and 100 pg/mL and in whom Ct spikes were over 100 pg/mL on the calcium stimulation test, were included in the study. The participants were between 23 and 79 years old, with an average age of 56 years. There were 123 individuals aged 50 and older and 53 individuals younger than 50 (Table 1). All patients had morphological changes on ultrasound in the thyroid gland. In total, 66 patients (37.5%) had a solitary nodule, 52 patients (29.5%) had micronodal changes in both thyroid lobes, 34 patients (19.3%) had a multinodular goiter, and 24 patients (13.6%) had diffuse goiter, usually due to underlying autoimmune disease (Graves’ disease or Hashimoto thyroiditis—HT). The size of the nodules, as measured by ultrasound examination, ranged from 3.3 to 44.0 mm, with an average of 14.2 ± 7.7 mm. All patients underwent a preoperative ENT examination. Twenty-three patients had overt hypothyroidism and preoperatively received l-thyroxine replacement therapy in doses from 25 to 150 mcg. Another four patients had a subclinical form of HT.
All patients included in the study underwent total thyroidectomy. Among them, 13 patients (7.6%) underwent unilateral central neck dissection, while 10 patients (5.8%) underwent bilateral central neck dissection. In our series, none of the patients underwent lateral neck dissection.
The average bCt level was 25.3 ± 14.6 pg/mL (10.0 to 81.2 pg/mL). The average peak Ct level after stimulation was 667.1 ± 462.4 pg/mL (108.0 to 3007.0 pg/mL). There was no statistically significant difference between the bCt and sCt values across genders. However, a statistically significant difference in Ct values was observed before and after stimulation with calcium agents, especially when comparing patients younger than 50 years old to those aged 50 years or older (Table 1).

3.1. Confirmed Cases of MTC

Based on postoperative PH analysis, 36 patients (20.5%) had MTC, while in 119 patients, CCH was found. Twenty-one patients had neither MTC nor CCH but other benign or malignant thyroid disorders, such as papillary thyroid carcinoma, follicular adenoma, thyroid follicular nodular disease, HT, or follicular adenoma (Table 2). The characteristics of patients with a verified diagnosis of MTC are summarized in Table 3.
The patients were divided into three groups: confirmed MTC, CCH, and those without C-cell pathology (Table 4). In patients with MTC, the mean bCt value was 38.6 ± 18.8 pg/mL (12.9 to 81.2 pg/mL), while the Ct value after stimulation with either CG or CC was 1029.8 ± 684.44 pg/mL (185.0 to 3007.0 pg/mL). In patients with PH-confirmed CCH, the bCt value was 21.8 ± 9.8 pg/mL (10 to 65.2 pg/mL), while the Ct value after stimulation with CG or CC was 581.7 ± 316.6 pg/mL (from 108.0 to 1818.0 pg/mL). In patients with other thyroid disorders, the bCt was 22.1 ± 17.6 pg/mL (11.0 to 75.8 pg/mL), while the mean Ct value after stimulation with CG or CC was 525.5 ± 371.0 pg/mL (122.0 to 1654.0 pg/mL) (Table 4).
Among patients with MTC, 31 (86.1%) were female and 5 (13.9%) were male, with a mean age of 59.2 ± 10.8 years (range: 36 to 78 years), indicating that 29 patients (80.6%) were older than 50. Mean values of bCt in female patients with confirmed MTC were 40.7 ± 18.7 pg/mL, while it was 25.5 ± 14.8 pg/mL in male patients. The mean value of sCt in females was 1069.5 ± 684.1 pg/mL, and it was 781.1 ± 706.5 pg/mL in males. There were no significant differences between genders for bCt (p = 0.09) and sCt (p = 0.39). The average tumor size in patients with confirmed MTC was 7.7 ± 5.6 mm (ranging from 1 to 30 mm) and did not correlate with bCt levels (Pearson = 0.08, p = 0.64) (Figure 1) or sCt levels (Pearson = 0.23, p = 0.15) (Figure 2).

3.2. ROC Analysis

ROC analysis was performed to identify a Ct threshold capable of distinguishing patients with MTC from other patients (patients with CCH and without C-cell pathology).
A bCt value of 31.1 pg/mL effectively distinguishes patients with MTC from others with an Sn of 69.4% and an Sp of 87.1% (p < 0.001; AUC = 0.786; 95%CI = 0.69–0.88; Youden index = 0.57) (Figure 3). The PPV for this cut-off value of bCt is 55%, and the NPV is 91.6%. Should sensitivity be raised, a lower calcitonin value of 16.2 pg/mL could serve as a cut-off (Sn = 88.9%; Sp = 37.1%; PPV 26.7%; NPV 92.9%) (Table 5).
An sCt value of 810.8 pg/mL after Ca-gluconate stimulation can help differentiate between patients with MTC and those with other thyroid diseases with an Sn of 60.9% and an Sp of 87.3% (p = 0.001; AUC = 0.733; 95%CI = 0.59–0.87; Youden index = 0.47) (Figure 4). Using this cut-off value, the PPV for sCt testing with CG is 66.7% and the NPV is 79.2%. If a higher sensitivity is desired, a lower sCt value of 388.4 pg/mL could be considered as an alternative cut-off, with a sensitivity of 82.6%, a specificity of 37.3%, a PPV of 37.3%, and an NPV of 82.6% (Table 6).
An sCt value of 1076 pg/mL after Ca-chloride stimulation makes it possible to distinguish between patients with MTC and those with other thyroid diseases with an Sn of 53.8% and an Sp of 92.1% (p < 0.05; AUC = 0.688; 95%CI = 0.49–0.88; Youden index = 0.46) (Figure 5). Using this cut-off value, the PPV for sCt testing with Ca-chloride is 50% and the NPV is 93.2%. With the Sn increasing to 76.9% and an Sp of 34.8%, the cut-off value is 431.5 pg/mL (PPV 14.7%; NPV 91.2%) (Table 7).

4. Discussion

The present study was designed and conducted to investigate whether the use of different calcium secretagogues in stimulating tests influences Ct cut-off values and to what extent. The study aimed to investigate the diagnostic strength of the stimulating tests using CC compared to CG.
Although rare, MTC represents an important clinical entity due to its unique biological behavior, histopathological characteristics, and frequent hereditary presentation. Those facts highlight the importance of obtaining a timely diagnosis. In our series, the prevalence for MTC was 2.2%. Reported prevalence rates typically range from 3% to 10% of all thyroid cancers [2,28]. However, with advances in the diagnosis and treatment of papillary thyroid carcinoma, the relative prevalence of MTC has recently declined to 1–2%, which is consistent with our findings [8,29,30].
Most patients with sporadic forms of MTC are diagnosed between the fourth and fifth decade of life, and there is slight female predominance (1:1.3) [5,31]. In our study, female patients outnumbered male patients by a ratio of six to one, with over 80% being older than 50 years. Mean values of bCt and sCt in female patients were higher than in males, with values of 40.7 ± 18.7 pg/mL vs. 25.5 ± 14.8 pg/mL and 1069.5 ± 684.1 pg/mL vs. 781.1 ± 706.5 pg/mL, respectively. The bCt and sCt values did not differ significantly between genders within our cohort (p = 0.09 for bCt; p = 0.39 for sCt). This result is inconsistent with the existing literature data, which predominantly reports statistically significant differences between genders, namely higher values in males, which affects cut-off values of Ct in daily clinical practice. The advocates of using separate cut-off values for males and females in stimulation tests had a more acceptable ratio of males to females [24,32], while in our study, the demographic data is based on only 36 cases with moderate calcitonin elevation, representing just 13.2% of all confirmed MTC cases in our clinic, with a significant dominance of female patients (86.1%), which influenced the mean values, and restricts the use of gender-specific Ct cut-offs.
In our study, nine patients with confirmed MTC (25%) had either a subclinical or an overt form of HT. Zayed et al. suggest that there is no higher incidence of MTC in patients with HT in the general population. However, a statistically significant association was found in female patients, although this finding was based on a limited number of cases [33]. Machens et al. disproved the association between CCH and HT in a study conducted on patients operated on at their center [34]. Shuetz et al. state that the prevalence of both MTC and CCH in patients with HT is 0.35%, which is lower than in patients with nodular disease [11]. Most of the evidence on the association between MTC and CCH and HT is reported in sporadic case reports [35,36,37,38,39,40].
Besides its local invasiveness and potency to lymph node and distant metastases, one characteristic that makes MTC remission difficult to achieve is the lack of radioiodine avidity [41], which is why a certain dose of radioiodine is recommended on initial surgical treatment. Since our study included only patients with moderately elevated bCt levels (10–100 pg/mL), and without ultrasonographic findings of lateral lymph node metastases (LNM), all patients had a total thyroidectomy performed, with 13 patients (7.6%) undergoing unilateral central dissection and 10 patients (5.8%) undergoing bilateral central dissection. No functional dissection of lateral lymph node metastasis (LNM) was performed, which is to be expected, as patients with higher bCt levels (>100 pg/mL) are typically those in whom lateral neck LNM is found. Park et al., in a large-scale study assessing the predictive value of basal calcitonin (bCt) levels for lymph node metastases (LNM), found no cases of lateral LNM and only five cases of central LNM in patients with bCt levels below 100 pg/mL. The group of authors also concluded that preoperative bCt levels can help guide the extent of initial surgical management [42]. Bae et al. propose Ct values of 226 pg/mL as a cut-off for ipsilateral central LNM, and 237 pg/mL for ipsilateral lateral LNM, with even higher values for contralateral LNM [43].
Prinzi et al. found a positive correlation between Ct levels and the T stage of tumors, with a Ct value of 60 pg/mL being the median for the T1a stage [44]. Numerous other studies have strongly supported this correlation [42,45,46,47,48]. In our study, 32 out of 36 confirmed MTC cases measured 1 cm or less, with a mean tumor size of 7.7 ± 5.6 mm and a mean basal calcitonin (bCt) level of 38.6 ± 18.8 pg/mL. The correlation between a Ct value and the size of medullary carcinoma was not found. Based on the highest calculated Youden index, we identified a bCt level of 31.1 pg/mL as the optimal cut-off for diagnosing MTC in this patient group, with a PPV of 55%. The values of 810.8 pg/mL (66.7% PPV) and 1076 pg/mL (50% PPV) were optimal thresholds for sCt, using CG and CC, respectively (Figure 3, Figure 4 and Figure 5; Table 5, Table 6 and Table 7).
Table 8 presents a comparison of our findings with those of similar studies that propose bCt and sCt cut-off values following CG stimulation testing.
A review of the literature on stimulatory tests performed with CC indicates that this method has been abandoned, since the studies in which CC is used (either on its own or in combination with Pg) span from 1974 to 1984. Even then, the studies were often conducted on healthy subjects who had no confirmed MTC, with the main focus of Ct research being due to its believed role as a calcemic peptide hormone [25,26,51].
Among the limited and dated data, McLean et al. proposed a stimulated calcitonin (sCt) cut-off value of 800 pg/mL for patients without a family history of MTC [52]. Wells et al. found CC stimulation to be less effective, but only relative to combined CG and Pg stimulation [53]. VanLathem et al. compared sCt levels in asymptomatic relatives of confirmed MEN2A patients to those in a control group of healthy individuals without a family history of MTC, using CC in combination with Pg [54]. However, their findings do not apply to our discussion, as our study included only cases of sporadic MTC, and none of the patients had a healthy thyroid gland. This positions our study as the first to directly compare stimulating tests using two different agents, both containing calcium as the active component, in a patient population for whom such testing is most relevant—those with moderately elevated basal calcitonin levels (10–100 pg/mL) and sporadic MTC.
The CC stimulation test was slightly inferior compared to the CG stimulation test (AUC 0.69 vs. 0.73), with slightly higher cut-off values needed to diagnose MTC-1076 vs. 810.8 pg/mL if a lower Sn value is obtained, or 431.5 vs. 388.4 pg/mL with a higher Sn value. This makes testing with CG somewhat more advantageous.
This study has several limitations that should be acknowledged. First, the analysis did not account for gender-specific calcitonin cut-off values, despite those being addressed in several previously cited studies. This decision was based on the absence of statistically significant differences in bCt and sCt levels between genders, the marked female predominance in our cohort (Table 1), and the primary objective of the study—to compare the diagnostic performance of two different stimulatory agents. Second, the study population was limited to patients with moderately elevated basal calcitonin levels (10–100 pg/mL), which may have contributed to the slightly lower AUC values observed when compared to studies with broader inclusion criteria (Table 8). Third, due to the retrospective design of the study and the non-randomized assignment of the secretagogue, the same patients were not tested with both CG and CC, which prevented a direct, within-subject comparison of the two stimulation tests. A prospective study, carried out on a larger patient pool, matched by gender, in which the same patients undergo both stimulation tests, spaced one week apart, would address these limitations, enable the use of gender-specific cut-off values, and prevent any possibility of bias. Our research group may consider such a design in the future, which may be contingent on the availability of CG.

5. Conclusions

Given the therapeutic challenges and overall aggressiveness of MTC, we recommend using cut-off values with higher sensitivity to guide initial surgical decisions in patients with moderately elevated basal calcitonin levels. These values are 16.2 pg/mL for bCt, 388.4 pg/mL for sCt following CG stimulation, and 431.5 pg/mL for sCt following CC stimulation. Although the CC stimulation test demonstrated slightly lower diagnostic performance compared to the CG test, it can still be reliably used in clinical practice, with awareness of its marginally higher cut-off threshold.

Author Contributions

Conceptualization, V.Z., J.I., G.Z. and K.T.; methodology, J.I., S.I., M.M. and A.P.; software, J.I. and M.B.; validation, K.T., M.J. and V.Z.; investigation, J.I., M.P. and K.T.; data curation, J.I., S.I., M.P. and M.M.; writing—original draft preparation, J.I.; writing—review and editing, K.T., M.J., G.Z. and N.K.; visualization, J.I. and K.T.; supervision, V.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Ministry of Science, Technological Development and Innovation, University of Belgrade, School of Medicine, grant number 451-03-137/2025-03/200110.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University Clinical Center of Serbia (1141/3; date: 25 April 2024).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Hoff, A.O.; Hoff, P.M. Medullary Thyroid Carcinoma. Hematol./Oncol. Clin. N. Am. 2007, 21, 475–488. [Google Scholar] [CrossRef] [PubMed]
  2. Pelizzo, M.R.; Mazza, E.I.; Mian, C.; Merante Boschin, I. Medullary thyroid carcinoma. Expert Rev. Anticancer. Ther. 2023, 23, 943–957. [Google Scholar] [CrossRef] [PubMed]
  3. Zhang, D.; Liang, N.; Sun, H.; Frattini, F.; Sui, C.; Yang, M.; Wang, H.; Dionigi, G. Critically evaluated key points on hereditary medullary thyroid carcinoma. Front. Endocrinol. 2024, 15, 1412942. [Google Scholar] [CrossRef] [PubMed]
  4. Cohen, E.G.; Shaha, A.R.; Rinaldo, A.; Devaney, K.O.; Ferlito, A. Medullary thyroid carcinoma. Acta Oto-Laryngol. 2004, 124, 544–557. [Google Scholar] [CrossRef] [PubMed]
  5. Raue, F.; Frank-Raue, K. Epidemiology and clinical presentation of medullary thyroid carcinoma. Recent Results Cancer Res. 2015, 204, 61–90. [Google Scholar] [PubMed]
  6. Băetu, M.; Olariu, C.A.; Stancu, C.; Caragheorgheopol, A.; Ioachim, D.; Moldoveanu, G.; Corneci, C.; Badiu, C. Thresholds of Basal- And Calcium-Stimulated Calcitonin for Diagnosis of Thyroid Malignancy. Horm. Metab. Res. 2021, 53, 779–786. [Google Scholar] [CrossRef] [PubMed]
  7. Trimboli, P.; Mian, C.; Piccardo, A.; Treglia, G. Diagnostic tests for medullary thyroid carcinoma: An umbrella review. Endocrine 2023, 81, 183–193. [Google Scholar] [CrossRef] [PubMed]
  8. Wells, S.A.; Asa, S.L.; Dralle, H.; Elisei, R.; Evans, D.B.; Gagel, R.F.; Lee, N.; Machens, A.; Moley, J.F.; Pacini, F.; et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015, 25, 567–610. [Google Scholar] [CrossRef] [PubMed]
  9. Faggiano, A.; Giannetta, E.; Modica, R.; Albertelli, M.; Barba, L.; Dolce, P.; Motta, C.; Deiana, M.G.; Martinelli, R.; Zamponi, V.; et al. Calcium-stimulated calcitonin test for the diagnosis of medullary thyroid cancer: Results of a multicenter study and comparison between different assays. Minerva Endocrinol. 2023, 48, 253–260. [Google Scholar] [CrossRef] [PubMed]
  10. Toledo, S.P.A.; Lourenço, D.M.; Santos, M.A.; Tavares, M.R.; Toledo, R.A. Correia-DeurIJEdM Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics 2009, 64, 699–706. [Google Scholar] [CrossRef] [PubMed]
  11. Schuetz, M.; Beheshti, M.; Oezer, S.; Novotny, C.; Paul, M.; Hofmann, A.; Bieglmayer, C.; Niederle, B.; Kletter, K.; Dudczak, R.; et al. Calcitonin measurements for early detection of medullary thyroid carcinoma or its premalignant conditions in Hashimoto’s thyroiditis. Anticancer Res. 2006, 26, 723–727. [Google Scholar] [PubMed]
  12. Machens, A.; Haedecke, J.; Holzhausen, H.J.; Thomusch, O.; Schneyer, U.; Dralle, H. Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbeck’s Arch. Surg. 2000, 385, 398–401. [Google Scholar] [CrossRef] [PubMed]
  13. Manatakis, D.K.; Bakavos, A.; Soulou, V.N.; Dimakis, C.; Tseleni-Balafouta, S. Reactive C cell hyperplasia as an incidental finding after thyroidectomy for papillary carcinoma. Hormones 2019, 18, 289–295. [Google Scholar] [CrossRef] [PubMed]
  14. Sakorafas, G.H.; Nasikas, D.; Thanos, D.; Gantzoulas, S. Incidental thyroid C cell hyperplasia: Clinical significance and implications in practice. Oncol. Res. Treat. 2015, 38, 249–252. [Google Scholar] [CrossRef] [PubMed]
  15. Perry, A.; Molberg, K.; Albores-Saavedra, J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: Separation of distinct histologic and biologic entities. Cancer 1996, 77, 750–756. [Google Scholar] [CrossRef]
  16. Albores-Saavedra, J.; Krueger, J.E. C-Cell Hyperplasia and Medullary Thyroid Microcarcinoma. Endocr. Pathol. 2001, 12, 365–377. [Google Scholar] [CrossRef] [PubMed]
  17. Guyétant, S.; Josselin, N.; Savagner, F.; Rohmer, V.; Michalak, S.; Saint-André, J.P. C-cell hyperplasia and medullary thyroid carcinoma: Clinicopathological and genetic correlations in 66 consecutive patients. Mod. Pathol. 2003, 16, 756–763. [Google Scholar] [CrossRef] [PubMed]
  18. Rosario, P.W.; Calsolari, M.R. Basal Serum Calcitonin, After Calcium Stimulation, and in the Needle Washout of Patients with Thyroid Nodules and Mild or Moderate Basal Hypercalcitoninemia. Horm. Metab. Res. 2017, 49, 129–134. [Google Scholar] [CrossRef] [PubMed]
  19. Colombo, C.; Verga, U.; Mian, C.; Ferrero, S.; Perrino, M.; Vicentini, L.; Dazzi, D.; Opocher, G.; Pelizzo, M.R.; Beck-Peccoz, P.; et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J. Clin. Endocrinol. Metab. 2012, 97, 905–913. [Google Scholar] [CrossRef] [PubMed]
  20. Lorenz, K.; Elwerr, M.; MacHens, A.; Abuazab, M.; Holzhausen, H.J.; Dralle, H. Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: A comparative analysis of calcium and pentagastrin stimulation of serum calcitonin. Langenbeck’s Arch. Surg. 2013, 398, 403–409. [Google Scholar] [CrossRef] [PubMed]
  21. Ubl, P.; Gincu, T.; Keilani, M.; Ponhold, L.; Crevenna, R.; Niederle, B.; Hacker, M.; Li, S. Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: The gender-specific differences. Endocrine 2014, 46, 549–553. [Google Scholar] [CrossRef] [PubMed]
  22. Băetu, M.; Olariu, C.A.; Nițu, I.; Moldoveanu, G.; Corneci, C.; Badiu, C. Safety of calcitonin stimulation tests with calcium. Hormones 2021, 20, 769–775. [Google Scholar] [CrossRef] [PubMed]
  23. Kiriakopoulos, A.; Giannakis, P.; Menenakos, E. Calcitonin: Current concepts and differential diagnosis. Ther. Adv. Endocrinol. Metabolism 2022, 13, 20420188221099344. [Google Scholar] [CrossRef] [PubMed]
  24. Mian, C.; Perrino, M.; Colombo, C.; Cavedon, E.; Pennelli, G.; Ferrero, S.; De Leo, S.; Sarais, C.; Cacciatore, C.; Manfredi, G.I.; et al. Refining calcium test for the diagnosis of medullary thyroid cancer: Cutoffs, procedures, and safety. J. Clin. Endocrinol. Metab. 2014, 99, 1656–1664. [Google Scholar] [CrossRef] [PubMed]
  25. Deftos, L.J.; Weisman, M.H.; Williams, G.W.; Karpf, D.B.; Frumar, A.M.; Davidson, B.J.; Parthemore, J.G.; Judd, H.L. Influence of age and sex on plasma calcitonin in human beings. N. Engl. J. Med. 1980, 302, 1351–1353. [Google Scholar] [CrossRef] [PubMed]
  26. Shamonki, I.M.; Frumar, A.M.; Tataryn, I.V.; Meldrum, D.R.; Davidson, B.H.; Parthemore, J.G.; Judd, H.L.; Defto, L.J. Age-Related Changes of Calcitonin Secretion in Females. J. Clin. Endocrinol. Metab. 1980, 50, 437–439. [Google Scholar] [CrossRef] [PubMed]
  27. Tausanovic, K.M.; Zivaljevic, V.R.; Zorić, G.V.; Jovanovic, M.D.; Stepanovic, B.G.; Milenkovic, M.G.; Paunovic, I.R. Predictive Value of Calcium Test for Preoperative Diagnosis of Medullary Thyroid Carcinoma in Patients with Moderately Elevated Basal Calcitonin. Endocr. Pract. 2021, 27, 1077–1081. [Google Scholar] [CrossRef] [PubMed]
  28. You, Y.N.; Lakhani, V.; Wells, S.A.; Moley, J.F. Medullary Thyroid Cancer. Surg. Oncol. Clin. N. Am. 2006, 15, 639–660. [Google Scholar] [CrossRef] [PubMed]
  29. Kim, M.; Kim, B.H. Current Guidelines for Management of Medullary Thyroid Carcinoma. Endocrinol. Metab. 2021, 36, 514–524. [Google Scholar] [CrossRef] [PubMed]
  30. Kitahara, C.M.; Sosa, J.A. The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 2016, 12, 646–653. [Google Scholar] [CrossRef] [PubMed]
  31. Viola, D.; Elisei, R. Management of Medullary Thyroid Cancer. Endocrinol. Metab. Clin. N. Am. 2019, 48, 285–301. [Google Scholar] [CrossRef] [PubMed]
  32. Papadakis, G.; Keramidas, I.; Triantafillou, E.; Kanouta, F.; Pappa, T.; Kaltzidou, V.; Tertipi, A.; Iordanidou, L.; Trivizaki, E.; Vecchini, G.; et al. Association of basal and calcium-stimulated calcitonin levels with pathological findings after total thyroidectomy. Anticancer Res. 2015, 35, 4251–4258. [Google Scholar] [PubMed]
  33. Zayed, A.A.; Ali, M.K.; Jaber, O.I.; Suleiman, M.D.; Ashhab, A.A.; Al_Shweiat, W.M.; Momani, M.S.; Shomaf, M.; AbuRuz, S.M. Is Hashimoto’s thyroiditis a risk factor for medullary thyroid carcinoma? Our experience and a literature review. Endocrine 2015, 48, 629–636. [Google Scholar] [CrossRef] [PubMed]
  34. MacHens, A.; Lorenz, K.; Weber, F.; Dralle, H. Clinical Significance of Coexistence of Hashimoto Thyroiditis and Graves’ Disease with Differentiated and Medullary Thyroid Cancer. Exp. Clin. Endocrinol. Diabetes 2022, 130, 381–385. [Google Scholar] [CrossRef] [PubMed]
  35. Malpani, S.; Tandon, A.; Panwar, H.; Khurana, U.; Kapoor, N.; Behera, G.; Gupta, V. Medullary thyroid carcinoma co-existent with Hashimoto’s thyroiditis diagnosed by a comprehensive cytological approach. Diagn. Cytopathol. 2020, 48, 386–389. [Google Scholar] [CrossRef] [PubMed]
  36. Abdullah, A.M.; Ali, R.M.; Salih, K.M.; Mohammed, K.K.; Kakamad, F.H.; Salih, A.M. Synchronous occurrence of papillary thyroid microcarcinoma, medullary thyroid carcinoma and Hashimoto thyroiditis in a single thyroid: A case report with literature review. Int. J. Surg. Case Rep. 2022, 93, 106888. [Google Scholar] [CrossRef] [PubMed]
  37. SamieeRad, F.; Emami, A. Synchronous Occurrence of Papillary Thyroid Carcinoma and Medullary Carcinoma in the Setting of Hashimoto’s Thyroiditis and Multi Nodular Goiter. Iran. J. Pathol. 2022, 27, 91–96. [Google Scholar] [CrossRef] [PubMed]
  38. Kim, H.Y.; Park, N.H. Concurrent Medullary Carcinoma and Hashimoto’s Thyroiditis: A Case Report with an Emphasis on US Features. J. Korean Soc. Radiol. 2023, 84, 1146–1151. [Google Scholar] [CrossRef] [PubMed]
  39. Mousa, U.; Gursoy, A.; Ozdemir, H.; Moray, G. Medullary thyroid carcinoma in a patient with Hashimoto’s thyroiditis diagnosed by calcitonin washout from a thyroid nodule. Diagn. Cytopathol. 2013, 41, 644–646. [Google Scholar] [CrossRef] [PubMed]
  40. Patel, B.; Roy, A.; Badhe, B.; Siddaraju, N. Cytologic aspects of an interesting case of medullary thyroid carcinoma coexisting with Hashimoto’s thyroiditis. J. Cytol. 2016, 33, 100–102. [Google Scholar] [PubMed]
  41. Maghsoomi, Z.; Emami, Z.; Malboosbaf, R.; Malek, M.; Khamseh, M.E. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: A systematic review. BMC Cancer 2021, 21, 579. [Google Scholar] [CrossRef] [PubMed]
  42. Park, H.; Park, J.; Choi, M.S.; Kim, J.; Kim, H.; Shin, J.H.; Kim, J.H.; Kim, J.S.; Kim, S.W.; Chung, J.H.; et al. Preoperative serum calcitonin and its correlation with extent of lymph node metastasis in medullary thyroid carcinoma. Cancers 2020, 12, 2894. [Google Scholar] [CrossRef] [PubMed]
  43. Bae, S.Y.; Jung, S.P.; Choe, J.H.; Kim, J.S.; Kim, J.H. Prediction of lateral neck lymph node metastasis according to preoperative calcitonin level and tumor size for medullary thyroid carcinoma. Kaohsiung J. Med. Sci. 2019, 35, 772–777. [Google Scholar] [CrossRef] [PubMed]
  44. Prinzi, A.; Frasca, F.; Russo, M.; Pellegriti, G.; Piticchio, T.; Tumino, D.; Belfiore, A.; Malandrino, P. Pre-Operative Calcitonin and CEA Values May Predict the Extent of Metastases to the Lateral Neck Lymph Nodes in Patients with Medullary Thyroid Cancer. Cancers 2024, 16, 2979. [Google Scholar] [CrossRef] [PubMed]
  45. Cohen, R.; Campos, J.M.; Salaün, C.; Heshmati, H.M.; Kraimps, J.L.; Proye, C.; Sarfati, E.; Henry, J.F.; Niccoli-Sire, P.; Modigliani, E. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2000, 85, 919–922. [Google Scholar] [CrossRef] [PubMed]
  46. Yip, D.T.; Hassan, M.; Pazaitou-Panayiotou, K.; Ruan, D.T.; Gawande, A.A.; Gaz, R.D.; Moore FDJr Hodin, R.A.; Stephen, A.E.; Sadow, P.M.; Daniels, G.H. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery 2011, 150, 1168–1177. [Google Scholar] [CrossRef] [PubMed]
  47. Opsahl, E.M.; Akslen, L.A.; Schlichting, E.; Aas, T.; Brauckhoff, K.; Hagen, A.I.; Rosenlund, A.F.; Sigstad, E.; Grøholt, K.K.; Jørgensen, L.H.; et al. The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway. Eur. Thyroid. J. 2019, 8, 159–166. [Google Scholar] [CrossRef] [PubMed]
  48. Ni, J.; Tu, P.; Ling, Y. Gender and tumor size-specific calcitonin cutoff value for diagnosing MTC in 10,618 patients with thyroid nodule surgery. Endocrine 2024, 86, 1097–1109. [Google Scholar] [CrossRef] [PubMed]
  49. Fugazzola, L.; Di Stefano, M.; Censi, S.; Repaci, A.; Colombo, C.; Grimaldi, F.; Magri, F.; Pagotto, U.; Iacobone, M.; Persani, L.; et al. Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: Updated thresholds and safety assessment. J. Endocrinol. Investig. 2021, 44, 587–597. [Google Scholar] [CrossRef] [PubMed]
  50. Niederle, M.B.; Scheuba, C.; Riss, P.; Selberherr, A.; Koperek, O.; Niederle, B. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays? Thyroid 2020, 30, 974–984. [Google Scholar] [CrossRef] [PubMed]
  51. Parthemore, J.G.; Deftos, L.J. The regulation of calcitonin in normal human plasma as assessed by immunoprecipitation and immunoextraction. J. Clin. Investig. 1975, 56, 835–841. [Google Scholar] [CrossRef] [PubMed]
  52. McLean, G.W.; Rabin, D.; Moore, L.; Deftos, L.J.; Lorber, D.; McKenna, T.J. Evaluation of provocative tests in suspected medullary carcinoma of the thyroid:heterogeneity of calcitonin responses to calcium and pentagastrin. Metabolism 1984, 33, 790–796. [Google Scholar] [CrossRef] [PubMed]
  53. Wells SAJr Baylin, S.B.; Linehan, W.M.; Farrell, R.E.; Cox, E.B.; Cooper, C.W. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann. Surg. 1978, 188, 139–141. [Google Scholar] [CrossRef] [PubMed]
  54. Van Lathem, J.J.; Vermaak, W.J.; Kuyl, J.M.; Mollentze, W.; Jansen, S.; Wolmaran, L.; Pelser, H.; Barry, R.; Kruger, A.J.; Wolfaardt, M.; et al. Experience with a provocative test of calcitonin release as a prospective screening for preclinical medullary thyroid carcinoma in MEN type 2A family members. J. Clin. Lab. Anal. 1992, 6, 384–390. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 15 01850 g001
Figure 1. Relationship between tumor size and basal calcitonin values.
Figure 1. Relationship between tumor size and basal calcitonin values.
Diagnostics 15 01850 g001
Diagnostics 15 01850 g002
Figure 2. Relationship between tumor size and peak values of stimulated calcitonin.
Figure 2. Relationship between tumor size and peak values of stimulated calcitonin.
Diagnostics 15 01850 g002
Diagnostics 15 01850 g003
Figure 3. ROC plot analysis of basal calcitonin.
Figure 3. ROC plot analysis of basal calcitonin.
Diagnostics 15 01850 g003
Diagnostics 15 01850 g004
Figure 4. ROC plot analysis of stimulated calcitonin after application of Ca-gluconate.
Figure 4. ROC plot analysis of stimulated calcitonin after application of Ca-gluconate.
Diagnostics 15 01850 g004
Diagnostics 15 01850 g005
Figure 5. ROC plot analysis of stimulated calcitonin after application of Ca-chloride.
Figure 5. ROC plot analysis of stimulated calcitonin after application of Ca-chloride.
Diagnostics 15 01850 g005
Table 1. Comparison of basal and stimulated calcitonin values based on patient demographics.
Table 1. Comparison of basal and stimulated calcitonin values based on patient demographics.
SexAge (Years)
Demographic MaleFemalep-value<50≥50p-value
N7010653123
Basal Ct25.2 ± 11.625.3 ± 16.40.9720.6 ± 1227.2 ± 15.2<0.01
Stimulated Ct669.5 ± 396.9663.4 ± 497.50.9534.3 ± 330.9724.3 ± 499.10.01
Table 2. Distribution of patients who were operated on based on pathohistological diagnosis.
Table 2. Distribution of patients who were operated on based on pathohistological diagnosis.
Pathohistological DiagnosisNumber of Patients%
Medullary thyroid carcinoma3620.5
C-cell hyperplasia11967.6
Papillary thyroid carcinoma52.8
Thyroid follicular nodular disease105.7
Hashimoto thyroiditis42.3
Follicular adenoma21.1
Table 3. Characteristics of patients with a verified diagnosis of MTC.
Table 3. Characteristics of patients with a verified diagnosis of MTC.
No.SexAge (Years)TNMTu Size (mm)TestBasal Ct (pg/mL)Stimulated Ct (pg/mL)Associated Pathology
1Female59T1NxMx4Ca-gluconate22.2195.8HT
2Female68T1NxMx5Ca-gluconate16.3248.0TFNB
3Male63T2NxMx15Ca-gluconate12.9266.6TFNB
4Female61T1NxMx8Ca-gluconate42.6317.0Follicular adenoma
5Female66T1NxMx4Ca-gluconate17.9403.7TFNB
6Female63T1NxMx8Ca-gluconate16.6483.9TFNB
7Female55T1NxMx5Ca-gluconate28.8488.0TFNB
8Female59T1NxMx9Ca-gluconate14.1542.8TFNB
9Female72T1NxMx8Ca-gluconate81.2620.4HT
10Female71T1NxMx6Ca-gluconate31.4833.5TFNB
11Female54T1NxMx5Ca-gluconate36.2839.3HT
12Female66T1NxMx6Ca-gluconate17.2990.0TFNB
13Female51T1NxMx6Ca-gluconate44.71217.3HT
14Female66T1NxMx7Ca-gluconate47.61300.0TFNB
15Female76T2NxMx25Ca-gluconate34.91342.1PTC
16Female64T1NxMx8Ca-gluconate47.01360.0TFNB
17Female42T1NxMx10Ca-gluconate78.01370.0HT
18Male45T1NxMx4Ca-gluconate21.11396.9TFNB
19Female60T1NxMx5Ca-gluconate47.01411.0TFNB
20Female72T1NxMx8Ca-gluconate47.21461.4TFNB
21Female61T1NxMx5Ca-gluconate48.01530.0TFNB
22Male56T1NxMx10Ca-gluconate48.01690.0TFNB
23Female63T1NxMx7Ca-gluconate47.03007.0TFNB
24Female44T1NxMx4Ca-chloride49.71125TFNB
25Female46T1N1Mx11Ca-chloride34.41300HT
26Female36T1NxMx3Ca-chloride14.0248HT
27Female53T1NxMx3Ca-chloride39.0433TFNB
28Male44T1NxMx3Ca-chloride32.0367PTC
29Female52T1NxMx9Ca-chloride40.0771HT
30Female51T1NxMx4Ca-chloride49.51405TFNB
31Female68T2NxMx30Ca-chloride50.12000PTC
32Female70T1NxMx8Ca-chloride75.5184HT
33Female78T1NxMx7Ca-chloride34.0637.0TFNB
34Female70T1NxMx8Ca-chloride77.02890TFNB
35Female66T1NxMx8Ca-chloride32.01300TFNB
36Male40T1NxMx1Ca-chloride34.0893PTC
Tu—tumor; Ct—calcitonin; HT—Hashimoto thyroiditis; TFNB—thyroid follicular nodular disease; PTC—papillary thyroid carcinoma.
Table 4. Basal and stimulatory calcitonin values in all three groups of patients.
Table 4. Basal and stimulatory calcitonin values in all three groups of patients.
PH DiagnosisBasal Calcitonin (pg/mL)Stimulated Calcitonin (pg/mL)
Medullary thyroid carcinoma38.6 ± 18.8 (12.9–81.2)1029.8 ± 684.4 (185.0–3007.0)
C-cell hyperplasia21.8 ± 9.8 (10–65.2)581.7 ± 316.6 (108.0–1818.0)
Other diseases of the thyroid gland22.1 ± 17.6 (11.0–75.8)525.5 ± 371.0 (122.0–1654.0)
Table 5. Diagnostic test parameters for basal Ct using different cut-off values.
Table 5. Diagnostic test parameters for basal Ct using different cut-off values.
Cut-Off (pg/mL)AUCSensitivitySpecificityPPVNPV
31.10.7969.4%87.1%55%91.6%
16.2 88.9%37.1%26.7%92.9%
Table 6. Diagnostic test parameters for Ca-gluconate sCt using different cut-off values.
Table 6. Diagnostic test parameters for Ca-gluconate sCt using different cut-off values.
Cut-Off (pg/mL)AUCSensitivitySpecificityPPVNPV
810.80.7360.9%87.3%66.7%79.2%
388.4 82.6%37.3%37.3%82.6%
Table 7. Diagnostic test parameters for Ca-chloride sCt using different cut-off values.
Table 7. Diagnostic test parameters for Ca-chloride sCt using different cut-off values.
Cut-Off (pg/mL)AUCSensitivitySpecificityPPVNPV
10760.6953.8%92.1%50%93.2%
431.5 76.9%34.8%14.7%91.2%
Table 8. Diagnostic test parameters for basal and Ca-gluconate-stimulated Ct using different cut-off values among different research studies.
Table 8. Diagnostic test parameters for basal and Ca-gluconate-stimulated Ct using different cut-off values among different research studies.
Ilic et al. (2025)AUCCut-Off (pg/mL)SensitivitySpecificityPPVNPV
Basal Ct-H0.7931.169.4%87.1%55%91.6%
Basal Ct-L16.288.9%37.1%26.7%92.9%
Stimulated Ct-H0.73810.860.9%87.3%66.7%79.2%
Stimulated Ct-L388.482.6%37.3%37.3%82.6%
Faggiano et al. (2023) [9]
Basal Ct-F0.819.275%82%84%72%
Stimulated Ct-F0.7944554%100%100%63%
Basal Ct-M0.763967%97%86%91%
Stimulated Ct-M0.961167%100%100%91%
Fugazzola et al. (2021) [49]
Basal Ct-F0.913075.9%93.7%88%86.5%
Stimulated Ct-F0.8479100%50%53.8%100%
Basal Ct-M0.973488.9%95%88.9%92.6%
Stimulated Ct-M0.9046694.4%80%68%94.2%
Niederle et al. (2020) [50]
Basal Ct-F0.942381%100%100%83%
Stimulated Ct-F0.8778069%100%100%76%
Basal Ct-M0.894353%100%100%67%
Stimulated Ct-M0.85150055%100%100%68%
Rosario and Calsolari (2017) [18]
Basal Ct-H/4750%100%100%92.1%
Basal Ct-L/24.6100%74.3%40%100%
Stimulated Ct-H/655.233.3%100%100%89.7%
Stimulated Ct-L/186.5100%60%30%100%
Mian et al. (2014) [24]
Basal Ct-F0.952681.8%97.9%94.7%92%
Stimulated Ct-F0.9379100%76.6%68.7%100%
Basal Ct-M0.946883.3%100%100%92.9%
Stimulated Ct-M0.9454477.8%85.4%68.4%89.2%
Colombo et al. (2012) [19]
Basal Ct-F118.7100%100%100%100%
Stimulated Ct-F0.98184100%92.9%6.6%100%
Basal Ct-M168100%100%100%100%
Stimulated Ct-M0.93162075%100%100%99.9%
AUC—area under the curve; PPV—positive predictive value; NPV—negative predictive value; H—higher cut-off value; L—lower cut-off value; F—female; M—male.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ilic, J.; Tausanovic, K.; Zoric, G.; Jovanovic, M.; Buzejic, M.; Ivanis, S.; Parezanovic, M.; Marinkovic, M.; Karamarkovic, N.; Petakov, A.; et al. Comparing the Diagnostic Efficacy of Different Calcitonin Stimulation Tests for Sporadic Medullary Thyroid Carcinoma: Calcium Gluconate vs. Calcium Chloride. Diagnostics 2025, 15, 1850. https://doi.org/10.3390/diagnostics15151850

AMA Style

Ilic J, Tausanovic K, Zoric G, Jovanovic M, Buzejic M, Ivanis S, Parezanovic M, Marinkovic M, Karamarkovic N, Petakov A, et al. Comparing the Diagnostic Efficacy of Different Calcitonin Stimulation Tests for Sporadic Medullary Thyroid Carcinoma: Calcium Gluconate vs. Calcium Chloride. Diagnostics. 2025; 15(15):1850. https://doi.org/10.3390/diagnostics15151850

Chicago/Turabian Style

Ilic, Jovan, Katarina Tausanovic, Goran Zoric, Milan Jovanovic, Matija Buzejic, Sara Ivanis, Milan Parezanovic, Milan Marinkovic, Nemanja Karamarkovic, Ana Petakov, and et al. 2025. "Comparing the Diagnostic Efficacy of Different Calcitonin Stimulation Tests for Sporadic Medullary Thyroid Carcinoma: Calcium Gluconate vs. Calcium Chloride" Diagnostics 15, no. 15: 1850. https://doi.org/10.3390/diagnostics15151850

APA Style

Ilic, J., Tausanovic, K., Zoric, G., Jovanovic, M., Buzejic, M., Ivanis, S., Parezanovic, M., Marinkovic, M., Karamarkovic, N., Petakov, A., & Zivaljevic, V. (2025). Comparing the Diagnostic Efficacy of Different Calcitonin Stimulation Tests for Sporadic Medullary Thyroid Carcinoma: Calcium Gluconate vs. Calcium Chloride. Diagnostics, 15(15), 1850. https://doi.org/10.3390/diagnostics15151850

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop